Medmira Stock Performance
MMIRF Stock | USD 0.01 0.08 85.44% |
MedMira holds a performance score of 9 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -17.39, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning MedMira are expected to decrease by larger amounts. On the other hand, during market turmoil, MedMira is expected to outperform it. Use MedMira jensen alpha and the relationship between the potential upside and period momentum indicator , to analyze future returns on MedMira.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in MedMira are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, MedMira reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Total Cashflows From Investing Activities | -69.7 K |
MedMira |
MedMira Relative Risk vs. Return Landscape
If you would invest 5.46 in MedMira on December 17, 2024 and sell it today you would lose (4.15) from holding MedMira or give up 76.01% of portfolio value over 90 days. MedMira is currently producing 9.1556% returns and takes up 74.7992% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than MedMira, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
Risk |
MedMira Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedMira's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as MedMira, and traders can use it to determine the average amount a MedMira's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1224
Best Portfolio | Best Equity | MMIRF | ||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
74.8 actual daily | 96 96% of assets are less volatile |
Expected Return
5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average MedMira is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MedMira by adding it to a well-diversified portfolio.
MedMira Fundamentals Growth
MedMira Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MedMira, and MedMira fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MedMira Pink Sheet performance.
Return On Asset | -0.23 | |||
Profit Margin | (2.27) % | |||
Operating Margin | (1.79) % | |||
Current Valuation | 36.69 M | |||
Shares Outstanding | 697.45 M | |||
Price To Earning | (3.72) X | |||
Price To Sales | 36.63 X | |||
Revenue | 952.13 K | |||
EBITDA | (1.07 M) | |||
Cash And Equivalents | 396.14 K | |||
Total Debt | 40 K | |||
Book Value Per Share | (0.02) X | |||
Cash Flow From Operations | (1.88 M) | |||
Earnings Per Share | (0) X | |||
Total Asset | 3.83 M | |||
About MedMira Performance
By analyzing MedMira's fundamental ratios, stakeholders can gain valuable insights into MedMira's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MedMira has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MedMira has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America, the Caribbean, Europe, the Asia Pacific, and internationally. The company was founded in 1993 and is headquartered in Halifax, Canada. Medmira operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about MedMira performance evaluation
Checking the ongoing alerts about MedMira for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MedMira help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.MedMira is way too risky over 90 days horizon | |
MedMira has some characteristics of a very speculative penny stock | |
MedMira appears to be risky and price may revert if volatility continues | |
MedMira has high likelihood to experience some financial distress in the next 2 years | |
MedMira has accumulated 40 K in total debt. MedMira has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MedMira until it has trouble settling it off, either with new capital or with free cash flow. So, MedMira's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MedMira sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MedMira to invest in growth at high rates of return. When we think about MedMira's use of debt, we should always consider it together with cash and equity. | |
The entity reported the revenue of 952.13 K. Net Loss for the year was (1.83 M) with loss before overhead, payroll, taxes, and interest of (512.51 K). | |
MedMira has accumulated about 396.14 K in cash with (1.88 M) of positive cash flow from operations. | |
Roughly 70.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing MedMira's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MedMira's stock is overvalued or undervalued compared to its peers.
- Examining MedMira's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MedMira's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MedMira's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MedMira's pink sheet. These opinions can provide insight into MedMira's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MedMira Pink Sheet analysis
When running MedMira's price analysis, check to measure MedMira's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedMira is operating at the current time. Most of MedMira's value examination focuses on studying past and present price action to predict the probability of MedMira's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedMira's price. Additionally, you may evaluate how the addition of MedMira to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |